eXTReMe Tracker
Gene Therapy Net RSS feed Follow Gene Therapy Net on Twitter LinkedIn - Gene Therapy Net discussion group Facebook - Gene Therapy Net

Newsletter August 2011

Gene Therapy Net Banner
News: Genetically modified cells destroy leukaemia tumours
Scientists for the first time have used gene therapy to successfully destroy cancer tumours in patients with advanced disease - a goal that has taken 20 years to achieve. Researchers at the University of Pennsylvania engineered patients' own pathogen-fighting T-cells to target a molecule found on the surface of leukaemia cells.
The altered T-cells were grown outside of the body and infused back into patients suffering from late-stage chronic lymphocytic leukaemia (CLL), which affects the blood and bone marrow and is the most common form of leukaemia.

Read more...

Book: Evolution: A View from the 20th Century
Evolution: A View from the 20th Century describes the many ways that cells reorganize their own genomes in the course of evolution. This genome restructuring involves processes such as symbiogenesis, horizontal DNA transfer, and natural genetic engineering within the cell. These natural processes, as homologous recombination, transposition and site-specific recombination have already done, can provide models for artificial genetic engineering. Hopefully, increased focus on the evolutionary capabilities of living cells will expand the range of technologies available for gene therapy.
Read more...

Poll: The development of which type of adenoviral vector for (solid) cancer gene therapy treatments is most promising and should be supported?
Gene Therapy Net started a new poll regarding the development of adenoviral vectors for cancer gene therapy. What do you think? Vote now!
1- Suicide gene therapy adenoviral vectors expressing HSV-TK, or
2- Tumor specific replication competent adenoviral vectors (like CrAd), or
3- Immuno stimulating adenoviral vectors (like GM-CSF expressing), or
4- Tumor antigen expressing adenoviral vectors (like Mart-1 for melanoma)

Vote now...

Conference: Cancer Research Global Summit
Join us Aug 30-31 at Appel Consulting's Annual Cancer Research Global Summit. Network with senior level executives from the top 20 pharmaceutical and biotechnology industries. Our summit will focus on The Future of Cancer Therapeutics: Accelerating Progress at the Molecular. Hear updates from industry analysts on, the implementation of new technologies & novel agents. Why Label Free Biomolecular Analysis for Drug Discovery could be beneficial and key for future breakthroughs. Scientific presentations will provide in-depth coverage of developing adoptive cellular therapy for Cancer, with sessions dedicated to pre-clinical models and early stage trials of engineered T cells.
Aug 30-31, 2011 | London, United Kingdon

Online registration...

Conference: Vaccine Research Global Summit
Join us, at Appel Consulting's Annual Vaccine Research Global Summit. Network with senior level executives from the top 20 pharmaceutical and biotechnology industries. Our summit will focus on Exploring Innovation in Vaccine Research and development. Hear key addresses from industry leaders concerning commercial and business development of novel adjuvant vaccines. Scientific presentations will provide in-depth coverage on topics including accelerating vaccine research, practical considerations for the design and conduct of vaccine clinical trials, challenges of conducting global vaccination studies and vaccine manufacturing with sessions dedicated to using the avian embryonic stem cell line.
Sept 27-28, 2011 | London, United Kingdom

Online registration...

Company: Cardium Therapeutics
Cardium (NYSE Amex: CXM) is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium lifestyle medicinals brand platform.

The Company's lead product candidates include: (1) Excellagen(tm) topical gel, for wound care management, which Cardium plans to market launch in the fourth quarter subject to pending FDA 510(k) clearance; and (2) Generx(r), a DNA-based angiogenic cardiovascular biologic for patients in international markets with coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. News from Cardium is located at www.cardiumthx.com.

Read more...

Conferences
- 16 – 18 August 2011, ImVacS: The Immunotherapeutics & Vaccine Summit, Cambridge, MA
- 19 - 21 September 2011, Phacilitate’s 1st Asian Cell & Gene Therapy Forum, Singapore
- 21 - 23 September 2011, Annual Meeting of the Spanish Society of Gene and Cell Therapy (SETGyC), Zaragoza, Spain
- 26 - 27 September 2011, ASGCT - NIH Gene Therapy Symposium, Bethesda, MD
- 27 - 31 October 2011, European Society Of Gene & Cell Therapy (ESGCT) and the British Society of Gene Therapy (BSGT) collaborative Congress 2011, Brighton, UK
- 8 November 2011, 4rd annual Workshop on Genome Engineering, Seattle, WA
- 16 - 18 November 2011, 10th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases. Focus Topic: Cell Trafficking and the Niche, Sonoma, CA
- 30 January - 1 February 2012, Phacilitate 8th Annual Cell & Gene Therapy Forum 2012, Washington DC, MD
- 2 -5 February 2012, Up Close and Personalized, International Congress on Personalized Medicine, Florence, Italy
- 16 – 20 May 2012, American Society of Gene and Cell Therapy (ASGCT) 15th Annual Meeting, Philadelphia, PA
- 5 – 8 June 2012, International Society for Cellular Therapy (ISCT) 18th Annual Meeting, Seattle, WA
- 5 – 6 October 2012, International Society for Cell & Gene Therapy of Cancer - 2012 Singapore Conference, Singapore
- 27 - 31 October 2012, The 11th Annual Meeting of the French Society of Cell and Gene Therapy (SFTCG), Versailles, France

Read more...

Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines. Other information websites created and maintained by the owner of Gene Therapy Net are Dengue Virus Net, Influenza Virus Net and Chikungunya Virus Net.
To unsubscribe from the Newsletter, please login and edit your subscription details or contact us. You are currently registered as: {subtag:name}, email address: {subtag:email}.